Duration of isolation and contagiousness in coronavirus disease 2019 (COVID-19) patients receiving tocilizumab and dexamethasone: A case series. (9th April 2023)

• Record Type: Journal Article
• Authors: Côté, Florence; Boivin, Guy; Loungnarath, Vilayvong; Ruest, Annie; Bestman-Smith, Julie; Carbonneau, Julie; Hamelin, Marie-Ève; Roy, Marie-Claude
• Is Part Of: Infection control and hospital epidemiology. Volume 44:Number 4(2023)
• Page Start: 655
• Page End: 658
• Publication Date: 2023-04-09
• Subjects: Nosocomial infections -- Epidemiology -- Periodicals; Health facilities -- Sanitation -- Periodicals; Hospital buildings -- Sanitation -- Periodicals; Cross Infection -- Periodicals; Epidemiology -- Periodicals; Hospitals -- Periodicals; Infection Control -- Periodicals; 614.44
• DOI: 10.1017/ice.2022.14
• Languages: English
• ISSNs: 0899-823X

Abstract

Abstract: We describe 10 patients with severe coronavirus disease 2019 (COVID-19) who received tocilizumab and dexamethasone. We correlated isolation duration with cycle thresholds (Ct) values of nucleic acid amplification tests, clinical state and viral cultures. Isolation duration exceeded 21 days for 7 patients due to positive viral cultures or Ct values <30.